Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells
GlobeNewswire - Wed Dec 17, 8:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), today announced the presentation of a poster at the 2014 San Antonio Breast Cancer Symposium. The presentation highlights Biocept's ability to identify patients who have developed HER2-positive CTCs during disease progression after an initial HER2-negative diagnosis by solid biopsy. The discovery of these patients, who may potentially be candidates for anti-HER2 treatment is made possible by OncoCEE-BR(TM), a breast cancer diagnostic developed using Biocept's CTC capture and analysis technology. The study was conducted at the Dana-Farber/Harvard Cancer Center.
BIOC: 2.48 (-0.04)
Biocept Expands Worldwide Microchannel Patent Protection to South Korea
GlobeNewswire - Mon Dec 15, 8:05AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
BIOC: 2.48 (-0.04)
Biocept Appoints Experienced Physician as Medical Director
GlobeNewswire - Wed Dec 03, 8:24AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.
BIOC: 2.48 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:45AM CST
FRO: 2.43 (-0.01), SCOK: 2.92 (-0.01), NES: 4.96 (-0.44), OIIM: 2.18 (+0.01), BDR: 2.36 (+0.06), FRED: 16.64 (+0.20), MDGN: 5.19 (-0.02), NKA: 3.64 (+0.03), BIOC: 2.48 (-0.04), RVLT: 1.28 (-0.02), DY: 33.68 (+0.41), NDRM: 5.90 (-0.19), CRNT: 0.98 (+0.02), QIHU: 61.47 (+2.58), NFEC: 1.69 (+0.15), RLI: 48.88 (-0.20), ACI: 1.78 (+0.01), APT: 2.55 (-0.03), LAKE: 8.94 (+0.07), CASY: 89.15 (+0.12)
Nasdaq stocks posting largest volume increases
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RESN: 8.79 (+0.45), FCVA: 4.34 (+0.10), GLBZ: 12.30 (unch), VGGL: 2.89 (+0.04), RDI: 12.78 (-0.18), CRDC: 0.69 (unch), BIOC: 2.48 (-0.04), WFD: 7.29 (+0.04), PLMT: 18.77 (+2.03), JAXB: 12.26 (+0.96), SUSQ: 13.43 (+0.01), RDIB: 12.46 (-0.42)
Biocept reports Q3 loss
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:55PM CST
BIOC: 2.48 (-0.04)
Biocept Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30, 2014.
BIOC: 2.48 (-0.04)
Biocept Launches Lung Cancer Offering
GlobeNewswire - Wed Nov 12, 7:54AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and Circulating Tumor Cells (CTCs), today announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company's CLIA-certified and CAP-accredited laboratory.
BIOC: 2.48 (-0.04)
Biocept reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:13AM CST
BIOC: 2.48 (-0.04)
Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the third quarter of 2014 on Thursday, November 13, 2014, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to discuss the financial results and provide a company update.
BIOC: 2.48 (-0.04)
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 2.35 (+0.03), BIOC: 2.48 (-0.04)
Market Maker Surveillance Report. ISSC, CBK, ANV, BIOC, OMAG, TCS, Losing Stocks With Lowest Price Friction For Tuesday, October 7th 2014
M2 - Wed Oct 08, 4:24AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4746 companies with "abnormal" market making, 1204 companies with positive Friction Factors and 3932 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Innovative Solutions and Support Inc (NASDAQ:ISSC), Christopher & Banks Corp (NYSE:CBK), Allied Nevada Gold Corp (NYSE:ANV), BioClinica Inc (NASDAQ:BIOC), Omagine Inc (OTC:OMAG), (NYSE:TCS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ANV: 0.88 (+0.02), CBK: 5.44 (-0.16), ISSC: 2.87 (-0.06), TCS: 20.22 (+0.20), BIOC: 2.48 (-0.04)
Biocept Expands Collaboration With MD Anderson Cancer Center
GlobeNewswire - Tue Oct 07, 7:39AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer.
BIOC: 2.48 (-0.04)
Biocept to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 13 Annual BIO Investor Forum on October 7, 2014 at The Palace Hotel in San Francisco.
BIOC: 2.48 (-0.04)
Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the Company has been granted a patent in China for its microfluidic channel technology used to capture CTCs. The granted patent is the subject of Chinese Patent No. ZL200780032530.2, entitled, "Detection or Isolation of Target Molecules Using a Microchannel Apparatus."
BIOC: 2.48 (-0.04)
Biocept to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Sep 04, 7:36AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a corporate overview at the following upcoming investor conferences:
BIOC: 2.48 (-0.04)
Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe
GlobeNewswire - Wed Sep 03, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the opposition period has expired for challenging the validity of its European Patent No. 1838442, entitled, "Cell Separation Using Microchannel Having Patterned Posts." This patent supports the proprietary microfluidics blood-based technology Biocept uses to capture CTCs.
BIOC: 2.48 (-0.04)
Biocept Provides Second Quarter Operational Update
GlobeNewswire - Thu Aug 14, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities and Exchange Commission of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2014.
BIOC: 2.48 (-0.04)